1982: Personalized Medicine: The Intersection of Genotype and Drug Responsiveness in the Treatment of Canine Pulmonary Hypertension
Grant Status: Closed
Genetic background is thought to alter the way animals and humans respond to disease and drug therapy. The unique DNA signature of an individual is now recognized as a pivotal influence on disease outcome during treatment and has become the central concept propelling the study of pharmacogenomics and individualized medicine. Dr. Stern will apply this cutting-edge knowledge to pulmonary hypertension in dogs, a common disease with serious consequences including exercise intolerance, respiratory distress, and sudden death. Dr. Stern has identified a mutation in the gene phosphodiesterase 5A (PDE5A), the target of a drug called sildenafil, and believes this mutation may influence responsiveness of dogs to the drug. Dr. Stern will evaluate the responsiveness of dogs to sildenafil through pre- and post- echocardiogram, identification of biological markers of disease, and quality of life questionnaires. Differences between treatment responses will be compared to genotype. He aims to establish a diagnostic test that allows clinicians to make treatment recommendations on a personalized basis and tailor the therapeutic approach to treatment of pulmonary hypertension.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.